

*3rd International Workshop on Interim PET in Lymphoma  
Menton, September 27, 2011  
Poster Discussion*

# **Poster discussion NHL**

***Ulrich Dührsen  
Department of Hematology  
University Hospital Essen***

# Poster discussion - NHL

*Clinically versus technically oriented studies*

## **16 abstracts on NHL**

7 clinically oriented studies

B102, B104, B107, [B111](#), B112, B114, B115

9 technically oriented studies

[B100](#), B101, B103, [B105](#), B106, [B108](#), B109, B110, B113

[4 brief presentations](#)

# Poster discussion - NHL

*Clinically oriented studies*

## **7 abstracts**

4 predictive value of interim PET

B104, B112, B114, B107

2 interim PET-guided therapy

B115, B102

1 interim PET combined with other prognostic markers

B111

# Predictive value of interim PET

*B104: Pregno et al, Turin, Alessandria, Novara and Florence, Italy*

Entity:	DLBCL
Patient selection:	None
No. of patients:	88, retrospective
Treatment:	6 – 8 x R-CHOP ( $\pm$ IFRT for bulk)
Interim PET:	PET2, PET3, PET4 (+ end-of-treatment PET)
Interval last chemo:	13 days
Method of evaluation:	Deauville criteria

<u>Results:</u>	<u>No. (%) pts.</u>	<u>2-yr-PFS</u>	
Interim PET negative	63 (72%)	85%	
Interim PET positive	25 (28%)	72%	p = 0.0475

Conclusions: Interim PET is not predictive of outcome.

# Predictive value of interim PET

*B112: González-Barca et al, GEL/TAMO, Spain*

Entity:	DLBCL		
Patient selection:	> 65 years IPI 0-5, < 65 years IPI 0-2		
No. of patients:	69, prospective		
Treatment:	6 x R-CHOP-14 (+ G-CSF)		
Interim PET:	PET2 (+ end-of-treatment PET)		
Interval last chemo:	10 – 14 days		
Method of evaluation:	Local evaluation		
<u>Results:</u>	<u>No. (%) pts.</u>	<u>29-mo-EFS</u>	
Interim PET negative	34 (49%)	91%	
Interim PET positive	35 (51%)	64%	p = 0.025
Conclusions:	Interim PET is predictive of outcome.		

# Predictive value of interim PET

*B114: Avigdor et al, Tel-Hashomer, Israel*

Entity: PMBCL  
Patient selection: None  
No. of patients: 30, retrospective  
Treatment: VACOPB, CHOP, R-VACOPB, R-CHOP  
Interim PET: Mid-treatment (after 6 weeks), PET3  
Interval last chemo: 7 – 21 days  
Method of evaluation: Juweid criteria

<u>Results:</u>	<u>No. (%) pts.</u>	<u>5-yr-PFS</u>	
Interim PET negative	16 (53%)	94%	
Interim PET positive	14 (47%)	57%	p = 0.015

Conclusions: Interim PET is predictive of outcome.  
Rituximab renders VACOPB and CHOP equipotent.

# Predictive value of interim PET

*B107: Izutsu et al, NKTSG, Japan*

Entity: Extranodal NK/T-cell lymphoma, nasal type  
Patient selection: Newly diagnosed stage IV or relapsed/refractory  
No. of patients: 16, retrospective  
Treatment: 2 x SMILE → SMILE / autoSCT / alloAST  
Interim PET: PET2  
Interval last chemo: 32 (22 – 72 days)  
Method of evaluation: Juweid criteria (central review)

<u>Results:</u>	<u>No. (%) pts.</u>	<u>2-yr-PFS</u>	
Interim PET negative	9 (56%)	62%	
Interim PET positive	7 (44%)	57%	p = 0.644

Conclusions: PET-negative patients may do well without SCT.

# Interim PET-guided therapy

*B115: Sehn et al, BC Cancer Agency, Canada*

Entity:	DLBCL
Patient selection:	None
No. of patients:	84, prospective
Treatment:	4 x R-CHOP → 2 x R-CHOP vs. 4 x R-ICE
Interim PET:	PET4
Interval last chemo:	21 – 28 days
Method of evaluation:	Juweid criteria

<u>Results:</u>	<u>No. (%) pts.</u>	<u>3-yr-PFS</u>
Interim PET negative	47 (56%)	} ~ 80%
Interim PET positive	27 (33%)	
Interim PET indeterm.	9 (11%)	

Conclusions: Interim PET-based therapy is feasible.



# Interim PET-guided therapy

*B102: Pardal et al, GEL/TAMO, Spain*

Entity: DLBCL  
Patient selection:  $\leq 65$  years, aalPI  $\geq 1$ ,  $\beta 2$ -MG $\uparrow$   
No. of patients: 65, prospective  
Treatment: 3 x R-MegaCHOP  $\rightarrow$  3 x R-MegaCHOP vs.  
2 x R-IFE + BEAM/ASCT  
Interim PET: PET2  
Interval last chemo: 15 – 21 days  
Method of evaluation: Local evaluation

<u>Results:</u>	<u>No. (%) pts.</u>	<u>2-yr-PFS</u>	
Interim PET negative	36 (55%)	~ 80%	
Interim PET positive	29 (45%)	~ 80%	p = > 0.1

Conclusions: Treatment deescalation in PET negative patients.

# Interim PET + other prognostic markers

*B111: Lanic et al, Rouen, France*

Entity:	DLBCL
Patient selection:	None
No. of patients:	57, retrospective
Treatment:	R-CHOP(-like)
Interim PET:	PET3, PET4 (+ end-of-treatment PET)
Additional investigation:	Gene expression profiling (ABC vs. GCB) IPI
<u>Results:</u>	Additional prognostic information